Long Term Safety Trial Comparing Intensive Treatment of Pulmonary Inhaled Human Insulin [insulin] With s.c. [subcutaneous] Insulin Aspart, Both in Combination With NPH [insulin suspension isophane], in Subjects With Type 1 Diabetes Mellitus

Trial Profile

Long Term Safety Trial Comparing Intensive Treatment of Pulmonary Inhaled Human Insulin [insulin] With s.c. [subcutaneous] Insulin Aspart, Both in Combination With NPH [insulin suspension isophane], in Subjects With Type 1 Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Insulin (Primary) ; Insulin aspart
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Oct 2009 Actual end date (Dec 2004) added as reported by ClinicalTrials.gov.
    • 22 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top